NCT05700669 - Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions

Metastatic Castration-resistant Prostate CancerRecurrent Epithelial Ovarian CancerBreast Cancer

Interventions

DRUG

AsiDNA

All patients will receive a loading dose of AsiDNA intravenously (D1, D2, D3) followed by weekly intravenous administrations in combination with Olaparib.

DRUG

Olaparib

Olaparib is given orally in combination with AsiDNA

Trial Locations (1)

78229

Next Oncology, San Antonio